异基因造血干细胞移植患者体内环孢素A和伏立康唑的相互作用
投稿时间:2021-11-12  修订日期:2022-03-16  点此下载全文
引用本文:王亚妮,吴迪,饶志,李茂星,葸瑞,任俊.异基因造血干细胞移植患者体内环孢素A和伏立康唑的相互作用[J].药学实践杂志,2022,40(3):277~280
摘要点击次数: 967
全文下载次数: 719
作者单位E-mail
王亚妮 中国人民解放军联勤保障部队第940医院临床药学科, 甘肃 兰州 730050
陕西省宝鸡市中医医院临床药学室, 陕西 宝鸡 721000
宁夏医科大学药学院, 宁夏 银川 750000 
 
吴迪 中国人民解放军联勤保障部队第940医院临床药学科, 甘肃 兰州 730050
宁夏医科大学药学院, 宁夏 银川 750000 
 
饶志 兰州大学第一医院药剂科, 甘肃 兰州 730050  
李茂星 中国人民解放军联勤保障部队第940医院临床药学科, 甘肃 兰州 730050
宁夏医科大学药学院, 宁夏 银川 750000 
 
葸瑞 中国人民解放军联勤保障部队第940医院临床药学科, 甘肃 兰州 730050  
任俊 中国人民解放军联勤保障部队第940医院临床药学科, 甘肃 兰州 730050 819149226@qq.com 
基金项目:甘肃省自然科学基金(20JR10RA005)
中文摘要:目的 分析异基因造血干细胞移植(Allo-HSCT)患者,静脉滴注伏立康唑(VRZ)与环孢素A(CsA)后的药物相互作用(DDI),为临床精准药物治疗提供依据。方法 进行一项患者自身对照研究,根据纳入排除标准,收集2019年1月—12月在某院进行Allo-HSCT的患者,采用LC-MS/MS法测定术前CsA给药后3~5 d的血药浓度2次,测定术后VRZ给药5~7 d后,CsA和VRZ同一时间的血药浓度2次,分别求其给药前后CsA、VRZ血药浓度的平均值。使用SPSS 20.0对VRZ给药前后CsA标准化血药浓度(C/D)的差异及VRZ血药浓度对CsA的C/D变化进行统计分析。结果 共纳入Allo-HSCT患者15例,用Wilcoxon符号秩和检验比较给药VRZ前后,CsA的C/D中位数变化,有显著性差异(P<0.001)。对VRZ血药浓度与CsA的C/D比值增幅进行Spearman相关性分析两者无显著相关性(ρ=?0.273,P=0.32)。结论 CsA与VRZ之间存在明显的药物相互作用(DDI),VRZ使CsA血药浓度显著升高,但VRZ与CsA之间的DDI程度大小与VRZ血药浓度无关,可能与患者个体差异有关。
中文关键词:环孢素A  伏立康唑  血药浓度  治疗药物监测  药物相互作用
 
Interaction between cyclosporine A and voriconazole in patients with allogeneic hematopoietic stem cell transplantation
Abstract:Objective To analyze the drug-drug interaction (DDI) between intravenous voriconazole (VRZ) and intravenous cyclosporine (CsA) in patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and provide an individualized and accurate clinical drug delivery. Methods In a self-contrast study, Allo-HSCT patients from January 2019 to December 2019 were enrolled according to the inclusion and exclusion criteria. These patients were treated with CsA and VRZ successively and the blood concentration of CsA and VRZ before and after 5-7 days of VRZ administration were determined with LC-MS/MS. The correlation between the concentration of VRZ and concentration/dose (C/D) ratio of CsA was analyzed with SPSS20.0. Results A total of 15 patients with ALLo-HSCT were enrolled. Wilcoxon sign rank sum test was used to compare the change of median C/D of CsA before and after VRZ administration, which had shown significant difference (P<0.001). Spearman correlation analysis was conducted on the increase of C/D ratio between VRZ and CsA, which had no significant correlation between them (ρ=?0.273, P=0.32). Conclusions There was obvious drug-drug interaction (DDI) between CsA and VRZ. VRZ increased CsA blood concentration significantly, but there was no significant correlation between VRZ blood concentration and the degree of concentration increase, which might be related to individual difference.
keywords:CsA  VRZ  blood concentration  therapeutic drug monitoring  drug interaction
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮